Amolyt Pharma: Funding, Investors & Team (Aug 2026)
Amolyt Pharma is using its team's proven proficiency in the development of therapeutic peptides to provide patients with uncommon endocrine and metabolic illnesses with life-altering therapies. AZP-3601, a parathyroid hormone analogue for the possible treatment of hypoparathyroidism, and AZP-3813, a potential treatment for acromegaly, are both in the portfolio of Amolyt Pharma. The interdisciplinary Amolyt Pharma team is prepared for impending milestones and the acceptance of new initiatives thanks to its extensive endocrinology network and the backing of a potent group of international investors.
Amolyt Pharma has raised $219M across 2 funding rounds on record, the most recent a Series C of $139M announced in Jan 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Amolyt Pharma Company Profile and Key Stats
Latest funding round on record: Jan 2023.
Amolyt Pharma Funding Rounds
Amolyt Pharma raised $80.0M in a Series B announced in Sep 2021.
1.3 years later, a Series C of $139M was announced in Jan 2023.
Amolyt Pharma Founders and Leadership Team
Contact details for the Amolyt Pharma team: 1 of 1 has an email address on file.
Start 14-day free trial →Amolyt Pharma Funding Compared to Other Biotechnology Startups
Amolyt Pharma's latest round of $139M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Amolyt Pharma in Biotechnology and Écully
Companies Similar to Amolyt Pharma
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Amolyt Pharma Funding FAQs
What does Amolyt Pharma do?
Amolyt Pharma is using its team's proven proficiency in the development of therapeutic peptides to provide patients with uncommon endocrine and metabolic illnesses with life-altering therapies. AZP-3601, a parathyroid hormone analogue for the possible treatment of hypoparathyroidism, and AZP-3813, a potential treatment for acromegaly, are both in the portfolio of Amolyt Pharma. The interdisciplinary Amolyt Pharma team is prepared for impending milestones and the acceptance of new initiatives thanks to its extensive endocrinology network and the backing of a potent group of international investors.
How much funding has Amolyt Pharma raised?
Amolyt Pharma has raised $219M across 2 rounds on record. The most recent is a Series C of $139M announced in Jan 2023.
When did Amolyt Pharma last raise funding?
Amolyt Pharma's most recent funding round on record is a Series C of $139M, announced in Jan 2023.
Who is the CEO of Amolyt Pharma?
Thierry Abribat is listed as CEO at Amolyt Pharma.
Where is Amolyt Pharma headquartered?
Amolyt Pharma is based in Écully, Rhone-Alpes, France.
How many employees does Amolyt Pharma have?
Amolyt Pharma is in the 11-50 employee band.
How does Amolyt Pharma's funding compare to other Biotechnology startups?
Amolyt Pharma's latest round of $139M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Amolyt Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Amolyt Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.